Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05036512 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate GBT021601 in Single and Multiple Doses in Healthy Participants
A Phase 1 study of Sickle Cell Disease, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 129
- Enrollment target
- 4
- Study locations
NCT05036512 is a Phase 1 study of Sickle Cell Disease that has completed, run by Pfizer. The registered enrollment target is 129 participants, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (56% lower). The trial reports 4 study locations across 2 states.
The verdict
NCT05036512, a Phase 1 study of Sickle Cell Disease, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 129 participants
- Enrollment target
- 4
- Study locations
Study Summary
This first in human study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and food effect of GBT021601, a hemoglobin S (HbS) polymerization inhibitor, in healthy participants.
Conditions Studied
Interventions
- DRUG GBT021601
Study Locations (4)
Western Australia
- Harry Perkins Institute of Medical Research - Nedlands
- Linear Clinical Research - Nedlands
- Oxford Compounding - North Perth
Texas
- ICON Early Phase Services, LLC - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 129 participants |
| Start Date | 2020-12-09 |
| Est. Completion | 2023-02-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05036512
The ClinicalTrials.gov registry entry for NCT05036512 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 129 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (56% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Sickle Cell Disease appearing as the primary indexed condition, and to 1 intervention - of which GBT021601 is the first listed.
NCT05036512 reports 4 study locations spanning 2 distinct geographic areas - top geographies include Western Australia, Texas.
Frequently Asked Questions
What is clinical trial NCT05036512 about?
NCT05036512 is a clinical study titled "A Study to Evaluate GBT021601 in Single and Multiple Doses in Healthy Participants". This first in human study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and food effect of GBT021601, a hemoglobin S (HbS) polymerization inhibitor, in healthy participants.
What is the current status of trial NCT05036512?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 129 participants. The study started on 2020-12-09. Estimated completion is 2023-02-07.
What conditions does trial NCT05036512 study?
This clinical trial studies the following conditions: Sickle Cell Disease.
What interventions are being tested in trial NCT05036512?
The interventions under investigation include: GBT021601 (DRUG).
Who is sponsoring clinical trial NCT05036512?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05036512 being conducted?
This trial has 4 study locations across Texas, Western Australia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
RECRUITING · Phase 1
-
Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies
RECRUITING · Phase 1
-
Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease
RECRUITING · Phase 1
-
PET Imaging of Vaso-Occlusive Crisis (VOC) in SCD
RECRUITING · Phase 1
-
Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease
RECRUITING · Phase 1
-
Methylphenidate to Address Attention and Executive Deficits Among Children With Sickle Cell Disease
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.